Nuclear medicine in prostate cancer management

di Evangelista - Ceci • 2022 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 4-6 giorni lavorativi

da €45,00 a € 42,75
accedi o registrati per vedere le promozioni a te riservate

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Avvisami con una mail appena disponibile

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

Prostate cancer imaging has evolved rapidly dur¬ing the last years, moving toward a more personalized approach. The comprehensive evaluation of tumor biology alongside the evaluation of different patterns of expression by cancer clones has become an attractive field of investigation for molecular imaging. Next-generation imaging represents a ground-breaking approach, deliver¬ing to patients more accurate diagnostic proce¬dures and leading clinicians to identify specific targets for radioligand therapy. The theragnostic approach-therapy and diagnosis using the same probe-represents, probably, one of the most important innovations in the management of prostate cancer. Hence, the rapid introduction into clinical practice of small molecules bind¬ing prostate-specific membrane antigen (PSMA) represents a brilliant example of how transla¬tional imaging should work. Prostate cancer, as one of the most frequent tumors and causes of death, still represents a hard enemy to fight, but next-generation imaging and radioligand therapy are innovative weapons that might contribute to improve outcomes and quality of life in men affected by the disease.